Pfizer prevails but Teva blasts Lipitor patent and backs UK pharmacies
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries is to remain enjoined from selling its generic version of Pfizer's anticholesterol blockbuster Lipitor (atorvastatin) in the UK, until it either wins in a patent invalidity trial, or until Pfizer's supplementary protection certificate (SPC) runs out on 6 May 2012 (the company recently received a six-month paediatric extension).